Condition
HER2-Positive Breast Carcinoma
ClinicalTrials.gov condition label
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov condition label, found in 10 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
10 shownImpact of Aromatase Inhibitor Therapy on Glucose Homeostasis and Diabetes RiskNCT06557057 · 2023-11-16
RECRUITINGImmune Response to Anti-HER2 Therapies in Patients With HER2-Positive Stage I-IV Breast CancerNCT04517838 · 2020-07-31
RECRUITINGCirculating Tumor DNA Based Minimal Residual Disease Detection for Patients With Early-Stage Breast CancerNCT07136493 · 2026-05-12
WITHDRAWNTesting the Role of FDG-PET/CT to Predict Response to Therapy Prior to Surgery for HER2-positive Breast Cancer, The DIRECT TrialNCT05710328 · 2023-05-10
ACTIVE_NOT_RECRUITINGTesting the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH TrialNCT04704661 · 2021-08-09
ACTIVE_NOT_RECRUITINGTesting the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Maintenance Treatment (Trastuzumab and Pertuzumab) After Initial Chemotherapy in a Phase Ib/II Trial for Advanced HER2 Positive Breast CancerNCT04108858 · 2021-05-20
TERMINATEDMeasuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair VariationsNCT04550494 · 2021-04-26
ACTIVE_NOT_RECRUITINGTVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast CancerNCT03179904 · 2017-08-03
COMPLETEDDocetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast CancerNCT02003209 · 2014-02-18
COMPLETEDWhole-Brain Radiation Therapy or Stereotactic Radiosurgery With or Without Lapatinib Ditosylate in Treating Patients With Brain Metastasis From HER2-Positive Breast CancerNCT01622868 · 2012-12-06
COMPLETEDCommon interventions
Biospecimen CollectionPROCEDURE5Computed TomographyPROCEDURE4TrastuzumabBIOLOGICAL3Biopsy ProcedurePROCEDURE2Laboratory Biomarker AnalysisOTHER2Magnetic Resonance ImagingPROCEDURE2PertuzumabBIOLOGICAL2Positron Emission TomographyPROCEDURE2AnastrozoleDRUG1Aromatase Inhibition TherapyDRUG1BiopsyPROCEDURE1CarboplatinDRUG1CeralasertibDRUG1ChemotherapyDRUG1CopanlisibDRUG1Cytology Specimen Collection ProcedureOTHER1DenifanstatDRUG1DocetaxelDRUG1EchocardiographyPROCEDURE1Echocardiography TestPROCEDURE1Electronic Health Record ReviewOTHER1ExemestaneDRUG1Fludeoxyglucose F-18OTHER1FulvestrantDRUG1Goserelin AcetateDRUG1
Leading sponsors
Trial status mix
ACTIVE_NOT_RECRUITING3
COMPLETED3
RECRUITING2
TERMINATED1
WITHDRAWN1
Phase mix
PHASE25
PHASE12
NA1
PHASE31
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.